Pdl.com creates medical solutions to treat diseases like cancer.
Title
PDL BioPharma :
Description
PDL BioPharma is a leader in the discovery, development and marketing of innovative therapies for serious or life-threatening illnesses, commercially focused on the acute care, hospital setting. Our therapeutic emphasis is on the areas of hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer .
Our roots are steeped in breakthrough antibody humanization technology — which enabled the development of some of the most innovative therapeutic advances of the past decade — including Synagis® for respiratory syncytial virus (RSV), Herceptin® for metastatic breast cancer, Avastin™ for metastatic colorectal cancer, Mylotarg® for acute myelogenous leukemia, and Xolair® for persistent asthma. In the nearly 20 years that we’ve been in business, we’ve established a strong financial foundation based on royalty revenues from licensing our technology to a variety of biotechnology and pharmaceutical partners.
In recent years, we’ve shifted from a royalty-driven enterprise into a commercial biopharmaceutical company. Through acquisitions and strategic partnerships, we’ve gained a commercial sales force and several marketed products. We’ve also expanded our development pipeline and focused our research capabilities, resulting in a strong pipeline of six innovative therapies in Phase 2 or Phase 3 development and a strategy to continue fueling that pipeline through both internal discovery and collaboration. Through these efforts, we’ve transformed our business and now we’re focused on becoming a sustainably profitable business enterprise.
Logos
